Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Tarsus Pharmaceuticals Inc

Healthcare US TARS

60.34USD
1.58(2.69%)

Last update at 2026-06-04T20:00:00Z

Day Range

58.9561.83
LowHigh

52 Week Range

12.5742.50
LowHigh

Fundamentals

  • Previous Close 58.76
  • Market Cap1297.80M
  • Volume432947
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-154.84701M
  • Revenue TTM42.56M
  • Revenue Per Share TTM1.35
  • Gross Profit TTM -17.76300M
  • Diluted EPS TTM-4.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -62.09500M -13.77200M -26.81000M -4.66900M -1.31800M
Minority interest - - - - -
Net income -62.09100M -13.82700M -26.81100M -4.67000M -1.31900M
Selling general administrative 44.95M 25.40M 8.17M 1.14M 0.45M
Selling and marketing expenses - - - - -
Gross profit 24.86M 54.95M - - -
Reconciled depreciation 0.33M 0.31M 0.25M 0.07M 0.00100M
Ebit -62.71200M -12.15700M -26.99800M -4.29800M -1.35000M
Ebitda -59.12700M -10.57900M -26.90200M -3.93000M -1.34900M
Depreciation and amortization 3.58M 1.58M 0.10M 0.37M 0.00100M
Non operating income net other -0.68300M -1.65100M - - -
Operating income -62.71200M -12.15700M -26.99800M -4.29800M -1.35000M
Other operating expenses 88.53M 69.18M 27.00M 4.30M 1.35M
Interest expense 2.20M 2.88M 0.19M 0.70M 0.00000M
Tax provision -0.00400M 0.06M 0.00100M 0.00100M 0.00100M
Interest income 3.50M 0.04M - - -
Net interest income 1.30M 0.04M 0.19M -0.04000M 0.03M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00400M 0.06M 0.00100M 0.00100M 0.00100M
Total revenue 25.82M 57.03M 0.00000M 0.00000M 0.00000M
Total operating expenses 87.57M 67.11M 27.00M 4.30M 1.35M
Cost of revenue 0.95M 2.08M - - -
Total other income expense net 0.62M -1.61500M 0.19M -0.37100M 0.03M
Discontinued operations - - - - -
Net income from continuing ops -62.09100M -13.82700M -26.81100M -4.67000M -1.31900M
Net income applicable to common shares -62.09100M -13.82700M -26.81100M -4.67000M -1.31900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 266.22M 227.86M 178.91M 171.97M 58.32M
Intangible assets 3.87M - - - -
Earning assets - - - - -
Other current assets 7.87M 0.00477M 4.04M 2.51M 0.04M
Total liab 69.24M 34.96M 12.18M 5.99M 64.32M
Total stockholder equity 196.99M 192.90M 166.73M 165.98M -6.00500M
Deferred long term liab - - - - -
Other current liab 18.39M 4.80M 1.49M 2.87M 0.30M
Common stock 0.00500M 0.00500M 0.00400M 0.00400M 0.00200M
Capital stock 0.00500M 0.00500M 0.00400M 0.00400M 0.00200M
Retained earnings -244.65600M -108.76300M -46.67200M -32.84500M -6.03400M
Other liab - 0.05M 0.11M 0.06M -
Good will - - - - -
Other assets 0.00000M 0.48M 0.18M 0.77M 0.00600M
Cash 224.95M 71.66M 171.33M 168.13M 57.95M
Cash and equivalents - - - - -
Total current liabilities 36.94M 15.43M 11.48M 5.39M 0.82M
Current deferred revenue - - - - -
Net debt -193.21500M -51.50500M -169.44100M -167.29800M -57.78800M
Short term debt 0.40M 0.72M 1.31M 0.28M 0.06M
Short long term debt - - - - -
Short long term debt total 31.73M 20.16M 1.89M 0.83M 0.16M
Other stockholder equity 441.64M 301.73M 213.40M 198.82M 0.03M
Property plant equipment - 0.96M 0.76M 1.24M 0.28M
Total current assets 256.13M 225.38M 175.95M 170.66M 58.03M
Long term investments 0.63M 0.37M - - -
Net tangible assets - 192.90M 166.73M 165.98M -6.00500M
Short term investments 2.50M 145.37M 0.48M - -
Net receivables 17.71M 3.58M 0.09M 0.02M 0.04M
Long term debt 29.82M 19.43M - - -
Inventory 3.11M 4.76M 175.68M - -
Accounts payable 18.15M 9.91M 8.68M 2.24M 0.46M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.00200M -0.07400M - -171.97200M -0.03800M
Additional paid in capital - - - - -
Common stock total equity - 0.00500M 0.00400M 0.00400M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -108.76300M -46.67200M -32.84500M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.51M 0.58M 1.13M 0.08M 0.00600M
Deferred long term asset charges - - - - -
Non current assets total 10.09M 2.49M 2.96M 1.32M 0.29M
Capital lease obligations 0.40M 0.77M 1.89M 0.83M 0.16M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -144.12300M -0.58600M -0.45600M -0.17500M -0.00700M
Change to liabilities 3.48M 5.75M 3.24M 0.24M 0.13M
Total cashflows from investing activities -144.62900M -0.58600M -0.45600M -0.17500M -0.00700M
Net borrowings -0.87500M 20.00M 20.00M 1.99M 1.99M
Total cash from financing activities 93.99M 0.02M 131.77M 59.45M 3.56M
Change to operating activities -1.77200M -2.43500M -1.79800M 0.27M -0.00100M
Net income -62.09100M -13.82700M -26.81100M -4.67000M -1.31900M
Change in cash -99.67200M 3.18M 110.18M 55.60M 2.37M
Begin period cash flow 171.33M 168.15M 57.97M 2.38M 0.00100M
End period cash flow 71.66M 171.33M 168.15M 57.97M 2.38M
Total cash from operating activities -49.03000M 3.75M -21.13800M -3.67300M -1.18300M
Issuance of capital stock 74.35M 0.00000M 131.43M 57.46M 3.56M
Depreciation 0.33M 0.31M 0.10M 0.04M 0.00100M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - -0.07300M 0.02M -0.03200M -0.00400M
Sale purchase of stock 74.94M 0.32M -0.02800M - -
Other cashflows from financing activities 19.64M -5.47300M 40.13M -0.17500M 3.56M
Change to netincome 13.96M 15.00M 3.97M 0.44M 0.00900M
Capital expenditures 0.51M 0.59M 0.46M 0.17M 0.00700M
Change receivables -3.49000M -0.07300M 0.02M - -
Cash flows other operating -0.20400M -3.42100M -2.37400M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -99.67200M 3.18M 110.18M - -
Change in working capital -0.95100M 1.37M 1.46M 0.48M 0.13M
Stock based compensation 13.46M 8.46M 0.84M 0.02M 0.00900M
Other non cash items 0.23M 5.79M 3.27M 0.13M -
Free cash flow -49.53600M 3.16M -21.59400M -3.84800M -1.19000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TARS
Tarsus Pharmaceuticals Inc		 1.58 2.69% 60.34 - - 77.74 6.90 66.61 -8.8182
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals Inc

15440 Laguna Canyon Road, Irvine, CA, United States, 92618

Key Executives

Name Title Year Born
Dr. Bobak R. Azamian M.D. Co-Founder, Pres, CEO & Chairman NA
Dr. Bryan Wahl J.D., M.D. Gen. Counsel & Corp. Sec. 1978
Ms. Dianne C. Whitfield M.S.W. Chief HR Officer 1977
Dr. Elizabeth Yeu Lin M.D. Chief Medical Advisor & Director 1978
Dr. D. Michael Ackermann Ph.D. Consultant 1982
Mr. Leonard M. Greenstein J.D. Chief Financial Officer 1976
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 1968
Mr. David Nakasone Head of Investor Relations NA
Ms. Adrienne Kemp Sr. Director of Corp. Communications NA
Mr. Matthew Rossen M.B.A. VP of Marketing 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions